Foresite Capital Management IV, LLC

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Foresite Capital Management IV, LLC reported 5 stock positions worth $197.9 million. Its top holding was Pharvaris (PHVS) at 47.2% of the portfolio, followed by Kura Oncology (KURA, 19.9%) and Kinnate Biopharma (KNTE, 13.0%). Its holdings were unchanged from Q4 2023.

Most Recent 13F
Q2 2026
Location
WEST HOLLYWOOD, CA
CIK
0001704132
Portfolio Value
$197.9M (Q1 2024)
SEC Filing
0001104659-24-061747 ↗ filed May 15, 2024

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $197.9M $197.9M Q1 2024 Q2 2024: $148.8M Q2 2024 Q3 2024: $153.0M Q3 2024 Q4 2024: $108.8M Q4 2024 Q1 2025: $111.1M Q1 2025 Q2 2025: $123.8M Q2 2025 Q3 2025: $182.6M Q3 2025 Q4 2025: $229.7M Q4 2025 Q1 2026: $237.1M Q1 2026 Q2 2026: $290.2M Q2 2026

Holdings 5 stocks · $197.9M
PHVS Pharvaris NV 47.16% 4,038,842 $93.3M No change
KURA Kura Oncology Inc. 19.94% 1,849,947 $39.5M No change
KNTE Kinnate Biopharma Inc. 13.00% 9,671,643 $25.7M No change
SNDX Syndax Pharmaceuticals Inc. 10.52% 875,000 $20.8M No change
LYEL Lyell Immunopharma Inc. 9.38% 8,325,000 $18.6M No change

Portfolio Sells Q4 2023 → Q1 2024
None this quarter.

Portfolio Buys Q4 2023 → Q1 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 6$290.2MPHVS, CYTK, EIKN, RLAY, XENE
Q1 2026 8$237.1MPHVS, CYTK, EIKN, LYEL, RLAY
Q4 2025 7$229.7MPHVS, CYTK, LYEL, MAZE, RLAY
Q3 2025 6$182.6MPHVS, CYTK, MAZE, LYEL, XENE
Q2 2025 6$123.8MPHVS, MAZE, LYEL, XENE, KURA
Q1 2025 5$111.1MPHVS, MAZE, LYEL, KURA, RLAY
Q4 2024 4$108.8MPHVS, KURA, LYEL, RLAY
Q3 2024 5$153.0MPHVS, KURA, SNDX, LYEL, RLAY
Q2 2024 4$148.8MPHVS, KURA, SNDX, LYEL
Q1 2024 5$197.9MPHVS, KURA, KNTE, SNDX, LYEL